Asked by: Ian Murray (Labour - Edinburgh South)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, what steps her Department is taking to increase Scotland’s (a) manufacturing capacity for and (b) delivery of cell and gene therapies.
Answered by Andrew Griffith - Minister of State (Department for Science, Innovation and Technology)
The government is investing significantly to support manufacturing and delivery of cell and gene therapies.
Since 2021, government has launched three UK-wide capital grant schemes – up to £118 million of funds – to incentivise manufacturing investments, including in advanced therapies. Last year, government announced a further £520 million to increase investment in Life Sciences manufacturing.
The UK is a world-leader in the development and manufacture of cell and gene therapies thanks to government investment in innovation and skills, including through the Cell and Gene Therapy Catapult which also coordinates the Advanced Therapy Treatment Centre network.
Asked by: Chi Onwurah (Labour - Newcastle upon Tyne Central)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, with reference to the policy paper entitled UK Science and Technology Framework, published on 6 March 2023, whether references in that paper to engineering biology include (a) gene therapy, (b) vaccine development and (c) other life sciences technologies.
Answered by Andrew Griffith - Minister of State (Department for Science, Innovation and Technology)
DSIT’s definition of engineering biology is set out in the National Vision for Engineering Biology, published in December 2023. Engineering biology includes products or services whose development draws on the tools of synthetic biology. This would capture all gene therapies, and vaccine and life science technologies which are developed using these tools. Engineering biology also delivers applications in other sectors of the economy including agriculture and chemicals.
Asked by: Chi Onwurah (Labour - Newcastle upon Tyne Central)
Question to the Department for Levelling Up, Housing & Communities:
To ask the Secretary of State for Levelling Up, Housing and Communities, with reference to paragraph 5.59, page 74 of the Spring Budget 2024, what his Department's (a) selection criteria and (b) rationale were for identifying Canary Wharf as the recipient hub of investment over other life sciences hubs.
Answered by Jacob Young - Parliamentary Under Secretary of State (Department for Levelling Up, Housing and Communities)
As the Government’s housing and regeneration agency, Homes England is tasked with accelerating house building and regeneration in all areas of the country. The brownfield regeneration scheme being supported at Canary Wharf includes over 500 homes in an area of high demand, responding to significant local need.
The Home Building Fund – Infrastructure Loans (HBF-IL) programme which supports this scheme provides infrastructure loans for mixed-use developments throughout England. Details of selection criteria can be found here: https://www.gov.uk/guidance/home-building-fund-infrastructure-loans.
Asked by: Chi Onwurah (Labour - Newcastle upon Tyne Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure adequate manufacturing capabilities for new (a) vaccines and (b) drugs in a pandemic.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
An established clinical countermeasures programme is a core component of our pandemic preparedness and response capability, including vaccines and therapeutics. The UK Biological Security Strategy, published in June 2023, reaffirms our ambition to scale up discovery, development, and manufacturing of therapeutics and vaccines within 100 days.
In the Autumn Statement 2023, the Chancellor announced £520 million for Life Sciences manufacturing to build resilience for future health emergencies and capitalise on the United Kingdom’s world-leading research and development. This follows previous investment through the Biomanufacturing Fund, to incentivise the manufacture of vaccines and therapeutics, to improve the UK’s health resilience to future pandemics.
In September 2023, the UK Health Security Agency agreed a deal for millions of life-saving vaccines to be produced, with end-to-end manufacturing in the UK, if a future influenza pandemic is ever declared. The advance purchase agreement means healthcare company CSL Seqirus will be on standby to produce over 100 million pandemic influenza vaccines from their manufacturing plant in Liverpool.
In December 2022, the Government and Moderna entered a strategic partnership to set up mRNA research, development, and manufacturing facilities in the UK. Under the partnership, Moderna will build a new Innovation and Technology Centre in the UK, with the capacity to produce up to 250 million vaccines per year, in the event of a pandemic.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, what steps she is taking to improve the life sciences translation process.
Answered by Andrew Griffith - Minister of State (Department for Science, Innovation and Technology)
The Government supports translational research in life sciences in several ways. MRC’s translational research group supports research through partnerships with other funders and major higher education institutions and through dedicated funding schemes. DSIT also co-funds the Health Innovation Network (HIN), alongside the Department of Health and Social Care. The network was established to help adoption and spread of innovation at pace and scale to improve health outcomes and generate economic growth. The Network connects the NHS, academic organisations, local authorities, charities and industry to facilitate change across health and social care economies, with a focus on improving outcomes for patients.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, whether she is taking steps with the Secretary of State for Health and Social Care to tackle regulatory systems that slow down research.
Answered by Andrew Griffith - Minister of State (Department for Science, Innovation and Technology)
Government is committed to delivering a regulatory system that is pro-innovation, easy to navigate and facilitates commercialisation of science and technology applications, as set out in the Science and Technology Framework.
Regulatory systems for life sciences are led by DHSC, and its arms-length-body the Medicines and Healthcare products Regulatory Agency recently launched a new, streamlined process for clinical trial applicants. The Department works with DHSC wherever appropriate on regulatory matters; for example, delivering the Government Chief Scientific Adviser's life sciences review and supporting on the wider implementation of the O'Shaughnessy Review into commercial clinical trials.
Asked by: Henry Smith (Conservative - Crawley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help encourage research into cardiovascular disease (a) treatment and (b) prevention.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department funds research into the treatment and prevention of cardiovascular disease through the National Institute for Health and Care Research (NIHR). In January 2023, the Department updated its areas of research interest (ARIs), which highlight to the patient, academic, clinical and life sciences community the areas where we want to expand our efforts and work together to systematically understand, intervene and improve public, patient, and service outcomes. ARI1 focuses on prevention, early diagnosis and appropriate intervention for people at increased risk of poor health, including cardiovascular disease. Supporting ARI1, the three NIHR Research Schools were awarded £10 million to deliver a collaborative programme of prevention research between 2023 and 2027. The programme will have a strong emphasis on capacity building. It will also encourage practitioners to participate in prevention research as a step towards establishing their own longer-term research careers and help address gaps between research and practice.
Asked by: Christian Wakeford (Labour - Bury South)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, what steps her Department is taking to promote (a) innovation and (b) research and development in (i) technology, (ii) green energy, (iii) healthcare and (iv) other key sectors of the economy.
Answered by Andrew Griffith - Minister of State (Department for Science, Innovation and Technology)
The Government is working to unleash the power of research & development and innovation across the economy - backed by the highest-ever levels of public spending on R&D, which will rise to £20 billion in 2024/25. As set out in our recent Science and Technology Framework update, the Department for Science, Innovation and Technology is removing barriers to success in technology-led sectors such as, telecoms, life sciences, and space.
Asked by: Catherine West (Labour - Hornsey and Wood Green)
Question to the Cabinet Office:
To ask the Minister for the Cabinet Office, whether the Government (a) is taking steps to ensure the security of genetic data of UK citizens and (b) has raised potential concerns relating to Chinese genomics companies as part of the US-UK Strategic Dialogue on Biological Security.
Answered by Alex Burghart - Parliamentary Secretary (Cabinet Office)
Organisations which hold sensitive biological data are subject to the UK General Data Protection Regulation (GDPR). In addition, organisations such as Genomics England, UK Biobank and NIHR BioResource consider national security in decision making about partnerships with other companies.
The Office for Life Sciences is undertaking a programme of work to assess how we can minimise the risks from biological data to protect our burgeoning bioeconomy, without stifling innovation, and build confidence in sharing personal data to improve health outcomes in the UK and across the world. This is being conducted in consultation with relevant Departments and Agencies across Government, and key partners such as Genomics England and UK Biobank.
Underpinned by the UK Biological Security Strategy and the U.S. Biodefense Strategy, the U.S.-UK Strategic Dialogue on Biological Security reflects a shared ambition to protect against a growing and diverse spectrum of biological threats. These risks include future pandemics as well as those that might arise from misuse of biotechnology and genomic data by state actors.
Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of developing a cross-departmental strategy including the (a) Department for Science, Innovation and Technology and (b) NHS to (i) support and (ii) promote expertise in cell and gene therapy innovation.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department recognises that advanced cell and gene therapies will be an important part of the future of healthcare and the life sciences industry. The Department has been considering the recommendations of the National Cell and Gene Therapy Vision for the UK, a report published by the Cell and Gene Therapy Catapult in March 2022, and the UK Strategic Stem Cell Forum’s latest report, A 10 Year Vision for Stem Cell Transplantation and Advanced Cellular Therapies, published in July 2022. As part of this we have been conducting stakeholder engagement across the cell and gene therapy ecosystem to further understand the challenges raised and whether there is a role for the Department in coordinating activity in this area. We will continue to work with our public sector partners to ensure a whole system approach to advanced therapies, building on existing strengths to ensure a joined-up research, regulatory, and health ecosystem.